Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Sanofi

Top French companies pay zero tax, despite year of record profits

The weekly magazine L'Obs is pleased to report that the leading French businesses made record profits in 2021, while the rest of us were cowering in fear of the coronavirus. But did they all pay reasonable taxes in France on those record earnings? L'Obs asked them just that.

Radio France Internationale

The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

How Is The Market Feeling About Sanofi?

Sanofi's (NASDAQ:SNY) short percent of float has fallen 22.22% since its last report. The company recently reported that it has 3.47 million shares sold short, which is 0.14% of all regular shares that are available for trading.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Sanofi Dives After FDA Slaps Its $3.7 Billion Drug With A Hold

Sanofi stock crumbled Thursday after the FDA slapped two of its final-phase studies with a hold, citing safety concerns.

Investors Business Daily

The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Sanofi Lowers Out-Of-Pocket Insulin Cost For Uninsured Patients

Sanofi SA (NASDAQ:SNY) said that uninsured diabetes patients in the U.S. will pay no more than $35 for a 30-day supply of insulin, down from $99. Sanofi said the new price would be effective from July 1. The announcement from Sanofi follows House passage (232-193) of the monthly cap in March, with just 12…

Benzinga

Finally An Omicron-Blocking Shot? Sanofi, GSK Say Yes

Sanofi stock bounded higher Friday after its GSK-partnered Covid shot tamped down on omicron infections in a Phase 3 study.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Benzinga Before The Bell: Gun Safety Bill. Bill Gates North Dakota Outrage, Sanofi-GSK's Covid-19 Vaccine's Omicron Efficacy And Other Top Financial Stories Friday, June 24

Reuters

Benzinga

Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron

Sanofi SA (NASDAQ:SNY) and GSK plc (NYSE:GSK) have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate. "Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," Sanofi said in a statement. The bivalent vaccine targets the…

Benzinga

Sanofi, GSK variant-specific COVID shot found effective against Omicron

(Fixes typographical error in media identifier)

Reuters

New antibody therapies fight cancer, drum up investment

Paris (AFP) - Antibody therapies are offering promising treatment breakthroughs for cancer and other illnesses, generating greater investor interest more than 20 years after they were first commercialised.

AFP

Peer review: Can this critical step in the publication of science research be kinder?

Democracy has been called the least worst system of government. Peer review is the least worst system for assessing the merit of scientific work.

The Conversation

The hard road for the Novavax vaccine

Novavax now in financial trouble after missing peak vaccinations

Salon

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

California wants to slash insulin prices by becoming a drugmaker. Can it succeed?

SACRAMENTO, Calif. — California is diving into the prescription drug business, attempting to achieve what no other state has done: produce its own brand of generic insulin and sell it at below-market prices to people with diabetes like Sabrina Caudillo.

The Guardian - UK

Drugmakers urged to give poorer nations access to more antibiotics

Antifungals also needed, says study, as drug resistance has increased faster than expected, particularly in sub-Saharan Africa

Benzinga

U.S. FDA Approves Regeneron And Sanofi's Lead Drug For Skin Inflammation In Children

The U.S.

Investors Business Daily

Regeneron Pharmaceuticals Dives On $1.1 Billion Deal To Rival Merck In Cancer

Regeneron stock tumbled Thursday after the company announced a deal to acquire the international rights to Sanofi-partnered cancer drug Libtayo.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Oil Stocks Lead Charge Of Breakouts And Buy Zones In New Uptrend

With a new uptrend underway, oil stocks like TotalEnergies and tech stocks like Synopsys set the stage for new breakouts.

Tribune News Service

Novavax missed its global moonshot but is angling to win over mRNA defectors

Novavax hitched its wagon to the global coronavirus pandemic. Before most Americans truly grasped the scope of the danger, the small Maryland biotech startup had secured $1.6 billion in U.S. funding for its COVID-19 vaccine. Its moonshot goal: delivering 2 billion shots to the world by mid-2021.

Benzinga

FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule

The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.

Benzinga

Sanofi To Pay €400K As Compensation For Epilepsy Drug-Related Side Effects

A French court has ordered Sanofi SA (NASDAQ: SNY) to pay more than €400,000 in damages to a French family whose child had autism caused by its epilepsy drug Valproate.

Investors Business Daily

Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now

AbbVie could soon pressure Regeneron in eczema treatment, an analyst said Friday as Regeneron stock hit a ceiling at its 200-day line.

Benzinga

Is Dario (DRIO) Health Eating Teladoc's (TDOC) Lunch? Q1 Earnings on Tap Thursday After Meeting with Sanofi (SNY)

Teladoc (NYSE: TDOC) stock recently cratered to a new 52 week low following it’s Q1 report. Some of it’s shortfall was attributed by management to longer sales cycles in the insurer and employer space in addition to competitive concerns.

Benzinga

Why Kymera Therapeutics Shares Are Falling Today

In its Q1 earnings release, Kymera Therapeutics Inc (NASDAQ:KYMR) announced the selection of the equivalent of 100 mg, in the fed state, as the dose for the Phase 1 patient cohort (Part C). The cohort is expected to enroll up to 20 patients with hidradenitis suppurativa (HS) and atopic dermatitis (AD). In…

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.